OnKure Therapeutics (OKUR) Stock Price, News & Analysis

Company Overview

OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.

Key Stats

• Today's Range: $2.35 to $2.53
• 50-Day Range: $1.83 to $2.99
• 52-Week Range: $1.70 to $20.00
• Volume: 93,296 shs
• Average Volume: 109,465 shs
• Market Capitalization: $32.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $32.33
• Consensus Rating: Buy

OnKure Therapeutics Stock Analysis - MarketRank™

OnKure Therapeutics scored higher than 63% of companies evaluated by MarketBeat, and ranked 397th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

OnKure Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

OnKure Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for OnKure Therapeutics are expected to grow in the coming year, from ($4.05) to ($3.41) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of OnKure Therapeutics is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of OnKure Therapeutics is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

OnKure Therapeutics has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for OKUR.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

OnKure Therapeutics does not currently pay a dividend.

Dividend Growth

OnKure Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for OKUR.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: -0.03

News Sentiment

OnKure Therapeutics has a news sentiment score of -0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.93 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for OnKure Therapeutics this week, compared to 1 article on an average week.

Search Interest

13 people have searched for OKUR on MarketBeat in the last 30 days. This is an increase of 225% compared to the previous 30 days.

MarketBeat Follows

2 people have added OnKure Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, OnKure Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,415,899.00 in company stock.

Percentage Held by Insiders

Only 2.30% of the stock of OnKure Therapeutics is held by insiders.

Percentage Held by Institutions

90.98% of the stock of OnKure Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

OKUR Stock Analysis - Frequently Asked Questions

How have OKUR shares performed this year?

OnKure Therapeutics' stock was trading at $8.60 at the beginning of 2025. Since then, OKUR shares have decreased by 72.1% and is now trading at $2.40.
View the best growth stocks for 2025 here.

How were OnKure Therapeutics' earnings last quarter?

OnKure Therapeutics, Inc. (NASDAQ:OKUR) announced its quarterly earnings results on Tuesday, May, 6th. The company reported ($1.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.41) by $0.22.

Who are OnKure Therapeutics' major shareholders?

Top institutional shareholders of OnKure Therapeutics include Affinity Asset Advisors LLC (2.93%) and ADAR1 Capital Management LLC (0.07%). Insiders that own company stock include Jason A Leverone and Nicholas A Saccomano.
View institutional ownership trends.

How do I buy shares of OnKure Therapeutics?

Shares of OKUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 5/06/2025
• Today: 6/29/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:OKUR
• Previous Symbol: NASDAQ:OKUR
• CIK: 1637715
• Web: reneopharma.com
• Phone: 858-283-0280
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $32.33
• High Stock Price Target: $34.00
• Low Stock Price Target: $30.00
• Potential Upside/Downside: +1,247.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 6 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($5.26)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$52.67 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -49.13%
• Return on Assets: -45.72%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.18
• Quick Ratio: 11.17

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.78 per share
• Price / Book: 0.31

Miscellaneous

• Outstanding Shares: 13,510,000
• Free Float: 13,199,000
• Market Cap: $32.42 million
• Optionable: N/A
• Beta: 0.42